Literature DB >> 9404669

Covalent protein-oligonucleotide conjugates for efficient delivery of antisense molecules.

S B Rajur1, C M Roth, J R Morgan, M L Yarmush.   

Abstract

Antisense oligonucleotides have been covalently attached to asialoglycoprotein (ASGP) via disulfide bond conjugation chemistry. These conjugates were characterized extensively by an array of chemical, chromatographic, and spectroscopic means. Multiple (approximately six) oligonucleotides can be conjugated to each ASGP molecule. The molecular conjugates were used to deliver antisense oligonucleotides complementary to the mRNA of the interleukin 6 signal transduction protein (gp130) to modulate the acute phase response of hepatoma (HepG2) cells in vitro. These conjugates were biologically active, as measured by inhibition of the cytokine-stimulated up-regulation of the acute phase protein haptoglobin. The level of inhibition was comparable to that found with previous technology featuring noncovalent complexes of ASGP-poly(L-lysine) and oligonucleotide. Because of the ability to control the stoichiometry of the conjugate and its unimolecular nature (as opposed to bimolecular for the noncovalent conjugates), this methodology holds great promise for further development and application.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9404669     DOI: 10.1021/bc970172u

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  14 in total

1.  Enhanced delivery of antisense oligonucleotides with fluorophore-conjugated PAMAM dendrimers.

Authors:  H Yoo; R L Juliano
Journal:  Nucleic Acids Res       Date:  2000-11-01       Impact factor: 16.971

2.  Covalent protein-oligonucleotide conjugates by copper-free click reaction.

Authors:  Santoshkumar L Khatwani; Jun Sung Kang; Daniel G Mullen; Michael A Hast; Lorena S Beese; Mark D Distefano; T Andrew Taton
Journal:  Bioorg Med Chem       Date:  2012-05-17       Impact factor: 3.641

Review 3.  Gene modulation for treating liver fibrosis.

Authors:  Kun Cheng; Ram I Mahato
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2007       Impact factor: 4.889

4.  Dendrimer-drug conjugates for tailored intracellular drug release based on glutathione levels.

Authors:  Raghavendra S Navath; Yunus E Kurtoglu; Bing Wang; Sujatha Kannan; Robert Romero; Rangaramanujam M Kannan
Journal:  Bioconjug Chem       Date:  2008-12       Impact factor: 4.774

5.  PAMAM dendrimers as delivery agents for antisense oligonucleotides.

Authors:  H Yoo; P Sazani; R L Juliano
Journal:  Pharm Res       Date:  1999-12       Impact factor: 4.200

Review 6.  Targeted TFO delivery to hepatic stellate cells.

Authors:  Ningning Yang; Saurabh Singh; Ram I Mahato
Journal:  J Control Release       Date:  2011-07-08       Impact factor: 9.776

7.  Targeted delivery of siRNA to hepatocytes and hepatic stellate cells by bioconjugation.

Authors:  Lin Zhu; Ram I Mahato
Journal:  Bioconjug Chem       Date:  2010-10-21       Impact factor: 4.774

Review 8.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

9.  Site-specific delivery of oligonucleotides to hepatocytes after systemic administration.

Authors:  Lin Zhu; Zhaoyang Ye; Kun Cheng; Duane D Miller; Ram I Mahato
Journal:  Bioconjug Chem       Date:  2007-09-13       Impact factor: 4.774

10.  HPMA polymer-based site-specific delivery of oligonucleotides to hepatic stellate cells.

Authors:  Ningning Yang; Zhaoyang Ye; Feng Li; Ram I Mahato
Journal:  Bioconjug Chem       Date:  2009-02       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.